Ilaris (generic: canakinumab) is a prescription medication used to treat rare genetic auto-inflammatory diseases known as Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). Ilaris is also approved to treat active systemic juvenile idiopathic arthritis (JIA) in patients aged 2 years and older.

Ilaris belongs to a group of drugs called interleukin-1beta blockers, which block a protein responsible for inflammation.

This medication comes in an injectable form to be injected just under the skin by your doctor or healthcare provider every 8 weeks.

Common side effects of Ilaris include cold symptoms, diarrhea, runny nose, and headache.